D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics - ...

Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 ...

Alumis' lead drug, ESK-001, is a potential best-in-class TYK2 inhibitor for treating plaque psoriasis and immunological diseases in general., with phase 3 trial data expected in 1H2026.

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast ...

Forgiving those who have repented of sin; Lordship of Christ; suffering of Christians. Who comforteth us in all our tribulation, that we may be able to comfort them which are in any trouble, by the ...

国家医疗保障局最新公告显示，浦东跨国企业——百时美施贵宝旗下全球首款口服酪氨酸激酶2（TYK2）变构抑制剂颂狄多（氘可来昔替尼片）已正式 ...

Akumin Inc., a leader in radiology and oncology services, unveiled the world's first Akumin AXIS Relocatable & Expandable Outpatient Center at the Radiological Society of North America (RSNA) meeting.

事后来看，百时美施贵宝赌对了，2022年9月Sotyktu获批上市，成为唯一一款没有黑框警告的JAK抑制剂，并成功带火了TYK2抑制剂赛道。 不过，百时美 ...

2024年11月28日，国家医疗保障局最新公告显示，百时美施贵宝旗下全球首款口服酪氨酸激酶2（TYK2）变构抑制剂颂狄多 ® （氘可来昔替尼片）已正式 ...

11月28日，国家医疗保障局最新公告显示，全球首款口服酪氨酸激酶2（TYK2）变构抑制剂颂狄多®（氘可来昔替尼片）已正式纳入《国家基本医疗保险 ...